{"id":"W4410455677","doi":"10.1016/j.esmoop.2025.104985","title":"414TiP Phase I/II study (Duravelo-1) of zelenectide pevedotin, a Bicycle Toxin Conjugate: Additional cohort (B-8) in patients with advanced breast cancer","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Cilag; University of Texas MD Anderson Cancer Center; EMD Serono; Daiichi Sankyo Europe; Servier; Genentech; Institut Gustave-Roussy; European Society for Medical Oncology; Basilea Pharmaceutica; Astellas Pharma; Eisai; Plexxikon; Seagen; Bayer HealthCare; G1 Therapeutics; Chugai Pharmaceutical; NGM Biopharmaceuticals; Incyte; Boston Pharmaceuticals; Agios Pharmaceuticals; Syndax Pharmaceuticals; Eisai Canada; Cholangiocarcinoma Foundation; BeiGene; Clovis Oncology; Loxo Oncology; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Centre Léon Bérard; MacroGenics; Celldex Therapeutics; Sanofi; Exelixis; Array BioPharma; Jazz Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; Merck KGaA; Celgene; Carrick Therapeutics; AstraZeneca; Ignyta; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Breast cancer; Conjugate; Cohort; Toxin; Medicine; Oncology; Internal medicine; Cancer; Microbiology; Biology; Mathematics","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007167544,0.001157528,0.001385812,0.0003136975,0.0002702477,0.0009226706,0.0006289072,0.0008673923,0.004243313],"category_scores_gemma":[0.0004176515,0.0004545893,0.001096713,0.0002848776,0.0006263517,0.000459203,0.0003277924,0.002438631,0.001334031],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007489995,"about_ca_system_score_gemma":0.001032309,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001638329,"about_ca_topic_score_gemma":0.003586285,"domain_scores_codex":[0.9997334,0.00010773,0.000009334401,0.00004365674,0.00002134822,0.00008464089],"domain_scores_gemma":[0.9997298,0.00003589377,0.00003280988,0.00002998726,0.00001734803,0.0001541753],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6844367,0.05001879,0.01254136,0.0007688124,0.001834583,0.0003609511,0.000278708,0.002868033,0.1014541,0.0004105809,0.007300299,0.137727],"study_design_scores_gemma":[0.530934,0.4159199,0.02778933,0.00005686487,0.001082822,0.0004645655,0.0001339353,0.001360519,0.01080755,0.0002596433,0.01113906,0.00005176376],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935271,0.001781904,0.0003707488,0.0004299818,0.0001080333,0.00061913,0.001267865,0.00009384597,0.001801525],"genre_scores_gemma":[0.9841278,0.002468063,0.001110574,0.0007581403,0.0001226885,0.0008201396,0.005193053,0.00005205223,0.005347595],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004243313,"threshold_uncertainty_score":0.01419532,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01195093419835612,"score_gpt":0.3557951380520973,"score_spread":0.3438442038537412,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}